{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:35:08Z","timestamp":1774611308999,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) is an uncommon non-Hodgkin lymphoma subtype, and its clinical and pathological characteristics remain unclear. PCNS-DLBCL patient data were retrospectively evaluated to determine clinical and pathological characteristics and prognostic factors. Furthermore, prognoses were calculated by Kaplan\u2013Meier and Cox regression models based on clinical observations. In total, 51 immunocompetent patients were enrolled. The median age was 55 (range, 16\u201382) years, and the male-to-female ratio was 3:2. Headache (n = 19; 37%) and the frontal lobe (n = 16; 31%) were the most common presenting symptom and location, respectively. The median follow-up was 33 (range, 3\u201386) months, and the median overall survival (OS) and progression-free survival (PFS) were 18 months [95% confidence interval (CI), 21.2\u201334.2] and 15 months (95% CI, 16.9\u201328.7), respectively. Ki-67, cluster of differentiation-3, and deep brain involvement were independent prognostic markers. Moreover, multifocal lesions and deep brain involvement were unfavorable independent prognostic markers for PFS. This study indicates that targeted drug development for adverse prognostic factors is possible and provides guidance for clinical treatment decision-making.<\/jats:p>","DOI":"10.3389\/fonc.2022.769895","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T06:24:21Z","timestamp":1657261461000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Impact of the Histopathological Index and Neuroimaging Features Status in Primary Central Nervous System Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Analysis of 51 Cases"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhou","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqiang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangxian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/1756285608101222","article-title":"Primary CNS Lymphoma","volume":"2","author":"Schlegel","year":"2009","journal-title":"Ther Adv Neurol Disord"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2409::AID-CNCR17>3.0.CO;2-V","article-title":"Will Primary Central Nervous System Lymphoma be the Most Frequent Brain Tumor Diagnosed in the Year 2000","volume":"79","author":"Corn","year":"1997","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/cncr.10643","article-title":"Decreasing Incidence Rates of Primary Central Nervous System Lymphoma","volume":"95","author":"Kadan-Lottick","year":"2002","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.3660","article-title":"Clinical Impact of the Cell-Of-Origin Classification and the MYC\/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group","volume":"35","author":"Staiger","year":"2017","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718494","article-title":"Distinct Patterns of B-Cell Receptor Signaling in non-Hodgkin Lymphomas Identified by Single-Cell Profiling","volume":"129","author":"Myklebust","year":"2017","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41408-020-00404-0","article-title":"Gene Expression Profiling-Based Risk Prediction and Profiles of Immune Infiltration in Diffuse Large B-Cell Lymphoma","volume":"11","author":"Merdan","year":"2021","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the Molecular Classification of Diffuse Large B-Cell Lymphoma by Immunohistochemistry Using a Tissue Microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.anndiagpath.2018.09.014","article-title":"Aggressive B Cell Lymphomas in the 2017 Revised WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","volume":"38","author":"Grimm","year":"2019","journal-title":"Ann Diagn Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS Lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00277-019-03821-9","article-title":"Primary Central Nervous System Lymphoma in China: A Single-Center Retrospective Analysis of 167 Cases","volume":"99","author":"Yuan","year":"2020","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-016-2358-8","article-title":"The Safety of Resection for Primary Central Nervous System Lymphoma: A Single Institution Retrospective Analysis","volume":"132","author":"Cloney","year":"2017","journal-title":"J Neurooncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00478","article-title":"Assessing the Safety of Craniotomy for Resection of Primary Central Nervous System Lymphoma: A Nationwide Inpatient Sample Analysis","volume":"8","author":"Yun","year":"2017","journal-title":"Front Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/35000501","article-title":"Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914","article-title":"The Use of Molecular Profiling to Predict Survival After Chemotherapy for Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"B17","article-title":"The Impact of BCL-2\/MYC Protein Expression and Gene Abnormality on Primary Central Nervous System Diffuse Large B-Cell Lymphoma","volume":"12","author":"Yin","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2014.1.90","article-title":"Diagnosis of 'Double Hit' Diffuse Large B-Cell Lymphoma and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma: When and How, FISH Versus IHC","volume":"2014","author":"Swerdlow","year":"2014","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 Protein Coexpression Contributes to the Inferior Survival of Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma and Demonstrates High-Risk Gene Expression Signatures: A Report From The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27396","article-title":"Prognostic Significance of MYC, BCL2, and BCL6 Rearrangements in Patients With Diffuse Large B-Cell Lymphoma Treated With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Plus Rituximab","volume":"118","author":"Akyurek","year":"2012","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114398","article-title":"MYC Protein Expression in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","volume":"9","author":"Gill","year":"2014","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1169-7","article-title":"Frequent Triple-Hit Expression of MYC, BCL2, and BCL6 in Primary Lymphoma of the Central Nervous System and Absence of a Favorable MYC(low)BCL2 (Low) Subgroup may Underlie the Inferior Prognosis as Compared to Systemic Diffuse Large B Cell Lymphomas","volume":"126","author":"Brunn","year":"2013","journal-title":"Acta Neuropathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23149","article-title":"Bcl-6 Predicts Improved Prognosis in Primary Central Nervous System Lymphoma","volume":"112","author":"Levy","year":"2008","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6893","article-title":"Immunohistochemical Profile and Prognostic Significance in Primary Central Nervous System Lymphoma: Analysis of 89 Cases","volume":"14","author":"Liu","year":"2017","journal-title":"Oncol Lett"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1789.2009.01074.x","article-title":"Primary Central Nervous System Lymphoma: Immunohistochemical Profile and Prognostic Significance","volume":"30","author":"Raoux","year":"2010","journal-title":"Neuropathology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.769895\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T06:24:24Z","timestamp":1657261464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.769895\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":25,"alternative-id":["10.3389\/fonc.2022.769895"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.769895","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"article-number":"769895"}}